ANNAPOLIS, MD - PPTA opposes New Jersey Assembly Bill 2003 passed by the New Jersey Assembly Appropriations Committee on June 13 that imposes a new tax on therapies used to treat bleeding disorders like hemophilia.
The U.S. Department of Health and Human Services (HHS) has appointed Plasma Protein Therapeutics Association (PPTA) industry expert Mary Gustafson to serve for a two-year term on its Advisory Committee on Blood Safety and Availability (ACBSA).
BRUSSELS, BELGIUM - The Plasma Protein Therapeutics Association (PPTA) hosted a discussion forum at the Dutch Parliament in The Hague yesterday. The forum was attended by representatives of the Dutch Ministry of Health, Members of the Dutch Parliament, the patient community and the national manufacturer of plasma protein therapies: Sanquin.
ANNAPOLIS, MD - The Plasma Protein Therapeutics Association commends the Florida legislature for allowing Medicaid recipients to continue to receive their clotting factor and the overlay services through the agency's hemophilia disease management program, rather than forcing them to switch to a managed care plan for their therapeutic needs.
ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) applauds Congress and President Obama for preserving patient access to safe and effective plasma protein therapies by repealing the 1099 tax-reporting provision.
ANNAPOLIS, MD – The Plasma Protein Therapeutics Association (PPTA) recently updated the Association's global website and its website on plasma donation with Spanish language translations of some materials posted online to better serve consumers.
PPTA collaborated with the patient community March 31 to host a Congressional staff briefing that focused on the uniqueness of plasma protein therapies; how they are made; the rare, chronic diseases they treat; and the importance of access.
Statements in the international media have described the events resulting from the retraction by several leading medical journals of a large number of articles describing scientific studies by a German physician, Joachim Boldt. Boldt was dismissed from his position as head of anesthesia in the Klinikum Ludwigshafen in the state of Rheinland-Pfalz in Germany in November 2010, following initial findings by a leading anesthesia journal that a paper describing a clinical study which Boldt published in the journal had been fabricated.
